Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Otsuka's Pletal will fuel major-market growth of vasoactive treatments. Sales of vasoactive treatments will grow from $177.6 million in 2001 to $291.8 million in 2011, according to a new Pharmacor report from Decision Resources entitled Peripheral Arterial Disease.

(Photo: )

"The progressive introduction of the novel therapy cilostazol (Otsuka's Pletal) in the symptomatic treatment class will drive significant class revenues," said John Earl, Ph.D., director of the Cardium group at Decision Resources. "However, these increases will be marginally offset by pressure on sales of beraprost (Toray/Yamanouchi's Dorner) in Japan following the forthcoming introduction of the Diagnosis Related Group (DRG) payment system, with physicians 'trading down' to cheaper treatments."

Disease Background-Peripheral Arterial Disease

Peripheral arterial disease (PAD) is predominantly a disease of old age, and occurs more frequently in men than women. Approximately 7 million individuals suffer from PAD in the United States. The principal symptom of PAD is intermittent claudication (IC), a disabling leg pain or ache on exertion that results from a reduction in blood flow to the lower limbs.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Peripheral Arterial Disease is a Cardium report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 


AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Shift in Medical Practice Will Deal Severe Blow to Sales of Current Hormonal Therapies for Prostate Cancer

View Now